Advanced

Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders

Werle, B; Sauckel, K; Nathanson, Carl-Michael LU ; Bjarnadottir, M; Spiess, E; Ebert, W and Abrahamson, M (2003) In Biological Chemistry1996-01-01+01:00 384(2). p.281-287
Abstract
Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The... (More)
Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The concentration of cystatin E/M was significantly higher in effusions of primary pleural tumours (mesotheliomas) compared to secondary pleural tumours and benign diseases. Furthermore, there was a significant correlation between the concentration of cystatin E/M of mesotheliomas and the pleural fluid tumour cell count and of cystatin C. The median values of cystatin F were significantly increased in parapneumonic/ empyema thoracis pleural effusions and tuberculous pleurisy compared to malignant pleural effusions, respectively. The concentration of cystatin F in benign effusions correlated significantly with diagnostic parameters and inflammation (total protein; lactate dehydrogenase; C-reactive protein). Finally, only in the group of parapneumonic/empyema thoracis was there a significant correlation between cystatin F and the neutrophil count. In conclusion, pleural effusions of different origin contain high levels of cystatin C, perhaps constituting the major part of an inhibitor reservoir. The level of cystatin E/M appears to be significantly associated with primary pleural tumours and cystatin F correlates with inflammatory processes of lung disorders. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
inhibitors, peptidase, mesothelioma, cysteine peptidases, lung inflammation, pleural effusion
in
Biological Chemistry1996-01-01+01:00
volume
384
issue
2
pages
281 - 287
publisher
De Gruyter
external identifiers
  • wos:000181175000012
  • pmid:12675521
  • scopus:0037300636
ISSN
1437-4315
DOI
10.1515/BC.2003.031
language
English
LU publication?
yes
id
006acc66-c9cb-442f-9fa4-76881143d97a (old id 317951)
date added to LUP
2007-09-24 07:46:42
date last changed
2018-02-18 03:33:27
@article{006acc66-c9cb-442f-9fa4-76881143d97a,
  abstract     = {Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The concentration of cystatin E/M was significantly higher in effusions of primary pleural tumours (mesotheliomas) compared to secondary pleural tumours and benign diseases. Furthermore, there was a significant correlation between the concentration of cystatin E/M of mesotheliomas and the pleural fluid tumour cell count and of cystatin C. The median values of cystatin F were significantly increased in parapneumonic/ empyema thoracis pleural effusions and tuberculous pleurisy compared to malignant pleural effusions, respectively. The concentration of cystatin F in benign effusions correlated significantly with diagnostic parameters and inflammation (total protein; lactate dehydrogenase; C-reactive protein). Finally, only in the group of parapneumonic/empyema thoracis was there a significant correlation between cystatin F and the neutrophil count. In conclusion, pleural effusions of different origin contain high levels of cystatin C, perhaps constituting the major part of an inhibitor reservoir. The level of cystatin E/M appears to be significantly associated with primary pleural tumours and cystatin F correlates with inflammatory processes of lung disorders.},
  author       = {Werle, B and Sauckel, K and Nathanson, Carl-Michael and Bjarnadottir, M and Spiess, E and Ebert, W and Abrahamson, M},
  issn         = {1437-4315},
  keyword      = {inhibitors,peptidase,mesothelioma,cysteine peptidases,lung inflammation,pleural effusion},
  language     = {eng},
  number       = {2},
  pages        = {281--287},
  publisher    = {De Gruyter},
  series       = {Biological Chemistry1996-01-01+01:00},
  title        = {Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders},
  url          = {http://dx.doi.org/10.1515/BC.2003.031},
  volume       = {384},
  year         = {2003},
}